BeyondSpring to Present Clinical Trial Data on Lead Asset, Plinabulin, at IASLC World Conference on Lung Cancer
BeyondSpring, Inc. - Ordinary Shares (BYSI)
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.beyondspringpharma.com
Company Research
Source: GlobeNewswire
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present clinical data on its lead asset, Plinabulin, during a poster presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer, being held September 23 to 26, 2018, in Toronto. Abstract #13016 Title: “Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy-Induced-Neutropenia and Thrombocytopenia in Non-Small Cell Lung Cancer Patients”First Author: Dr. Douglas BlayneyPoster Session: P1.01 – Advanced NSCLCDate: Monday, September 24, 2018Time: 9:45 a.m. to 6:00 p.m. EDTLocation: Metro Toronto Convention Centre North Building, Exhibit Hall, 255 Front St W, Toronto, ON M5V 2W6, Canada About BeyondSpring BeyondSpring is a global, clinical-stage biopharmaceutical company developi
Show less
Read more
Impact Snapshot
Event Time:
BYSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BYSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BYSI alerts
High impacting BeyondSpring, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
BYSI
News
- BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerGlobeNewswire
- Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?PR Newswire
- Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded [Yahoo! Finance]Yahoo! Finance
- BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsGlobeNewswire
BYSI
Sec Filings
- 3/18/24 - Form 6-K
- 2/26/24 - Form 6-K
- 2/14/24 - Form SC
- BYSI's page on the SEC website